Research programme: long-acting neuropsychiatric therapeutics - Teva

Drug Profile

Research programme: long-acting neuropsychiatric therapeutics - Teva

Alternative Names: NP 201; NP 202; NP-202-Teva; NP201-Teva; Risperidone implant - Teva; Risperidone long-acting - Teva; Ropinirole implant - Teva; Ropinirole long-acting - Teva

Latest Information Update: 12 Mar 2014

Price : $50

At a glance

  • Originator NuPathe
  • Developer Teva Pharmaceutical Industries
  • Class Amines; Indoles; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bipolar disorders; Parkinson's disease; Schizophrenia

Most Recent Events

  • 21 Feb 2014 NuPathe has been acquired by Teva Pharmaceutical Industries
  • 17 May 2013 NP 202 is available for licensing (http://www.nupathe.com)
  • 13 May 2013 NP 201 and NP 202 are still in preclinical trials for Parkinson's disease, Schizophrenia, and Bipolar disorder in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top